Psychosocial Interventions for Young Adults With Hip Pain

September 18, 2023 updated by: Michael C Willey
Psychosocial conditions are common in young adults with hip pain including depression, anxiety, pain catastrophizing, and narcotic use. The incidence of these conditions is not well defined. Interventions to optimize psychosocial conditions with non-surgical or surgical treatments has not been investigated. The goal of this project is to determine the incidence of psychosocial conditions in the young adult population with hip pain and determine if cognitive based therapy can improve clinical outcomes in these individuals.

Study Overview

Detailed Description

Over the last 3 decades there has been a drastic increase in the number of joint preservation surgeries performed for pre-arthritic hip conditions in the United States. Despite advances in surgical technique and the understanding of the biomechanics of impingement and dysplasia, failure rates range from 5-20% at early follow up, and can be even higher with continued monitoring. These failures are often attributed to the presence of pre-operative osteoarthritis, increased age, or unaddressed structural deformity. The influence of psychosocial factors on surgical and rehabilitative outcomes has been recognized in multiple populations, but has largely been ignored in individuals with hip pathology, in spite of growing recognition by clinicians as to how psychosocial factors may contribute to patient outcomes. Previous investigations have demonstrated poor mental health is associated with pre-operative narcotic use and lower physical function. Further, the investigators have identified certain psychiatric diagnoses as independent factors associated with failure of hip arthroscopy. Addressing these often complex psychosocial issues using cognitive based therapy has been successful in improving outcomes across a range of medical conditions. Further investigation into the incidence of these psychosocial conditions, their contributions to surgical and non-surgical outcomes, and interventions for mental health optimization need to be performed in musculoskeletal medicine, specifically in the developing field of hip preservation surgery. The goal of this project is to (1) understand the burden of maladaptive psychosocial traits in young adult patients with hip pain, and (2) reduce pain, decrease narcotic use, and improve physical function through psychosocial intervention delivered concomitantly during physical therapy. The investigators seek to maximize outcomes of individuals with non-arthritic hip dysfunction by addressing maladaptive behaviors so subjects can more effectively participate in rehabilitative treatment, and potentially, avoid the need for surgical management.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa
        • Contact:
        • Contact:
        • Sub-Investigator:
          • John Davison, MPH
        • Principal Investigator:
          • Elizabeth Scott, MD
        • Sub-Investigator:
          • Robert Westermann, MD
        • Sub-Investigator:
          • Jason Wilken, DPT, PhD
        • Sub-Investigator:
          • Amanda Paulsen, DPT
        • Sub-Investigator:
          • Michael Willey, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 39 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • We will enroll young adults (15-39) presenting to one of several physical therapy and orthopedic practices in the state of Iowa for treatment of nonarthritic hip pain.
  • Chief complaint of hip pain or dysfunction, and a diagnosis of a nonarthritic hip condition including labral tear, femoroacetabular impingement (FAI), snapping hip, femoral anteversion or dysplasia.

Exclusion Criteria:

  • Exclusion criteria will include age <15 or >40 years
  • Difficulty with written English
  • Treatment for alternative conditions such as trochanteric bursitis, hip dislocation, avascular necrosis or fracture.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cell Phone Based Cognitive Based Therapy
Young adults with hip pain
Cell phone application that provides support for individuals with psychosocial conditions.
Placebo Comparator: Placebo
Young adults with hip pain
Subjects in the control group will receive standard care.
Other Names:
  • Standard Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in level of Depression (DASS-21)
Time Frame: 8 weeks

Assessed using the Depression Anxiety Stress Scale (DASS-21) electronically administered patient reported outcome questionnaire

  • General adult population average total score: 9.43 (standard deviation (SD) 9.66), out of a total possible score of 63 points,
  • Indication of significant difference from normative data: Average score >1 SD above the General adult population average total score
  • General adult population average depression sub scale score: 2.83 (SD 3.87)
  • Values above 9.03 points in the depression subsection score correlate with clinical depression and generalized anxiety disorders
  • A change of 3.86 or more points in the depression subscore reliably represents clinical improvement.
8 weeks
Changes in level of Depression (PROMIS)
Time Frame: 8 weeks

Assessed using the Patient Reported Outcome Measures Information (PROMIS): Depression. An electronically administered patient reported outcome questionnaire

  • Normative T-score generated from US adult population data: mean 50 (SD 10).
  • For this study, an average T-score <40 would be considered significantly different compared to normative values.
  • The minimally important difference (MID) of 3.0-3.1 calculated from research in nonoperative treatment of knee osteoarthritis will be representative of clinical improvement at eight weeks.
8 weeks
Changes in level of Anxiety (DASS-21)
Time Frame: 8 weeks

Assessed using the Depression Anxiety Stress Scale (DASS-21) electronically administered patient reported outcome questionnaire

  • General adult population average total score: 9.43 (SD 9.66)
  • An average total score >1 SD above the mean would be considered significantly different from normative data
  • General adult population average anxiety subscale scores: 1.88±2.95
  • Average anxiety subsection score above 6.27 correlate with clinical depression and generalized anxiety disorders
  • A change of 3.85 or more points in the anxiety subscore reliably represents clinical improvement.
8 weeks
Changes in level of Anxiety (PROMIS)
Time Frame: 8 weeks

Assessed using the Patient Reported Outcome Measures Information (PROMIS): Anxiety. An electronically administered patient reported outcome questionnaire

  • Normative T-score generated from US adult population data: mean 50 (SD 10).
  • For this study, an average T-score <40 would be considered significantly different compared to normative values.
  • The minimally important difference (MID) of 2.3 to 3.4 calculated from research in nonoperative treatment of knee osteoarthritis will be representative of clinical improvement at eight weeks.
8 weeks
Changes in level of Stress (DAAS-21)
Time Frame: 8 Weeks

Assessed using the Depression Anxiety Stress Scale (DASS-21) electronically administered patient reported outcome questionnaire

  • General adult population average total score: 9.43 (SD 9.66)
  • An average total score >1 SD above the mean would be considered significantly different from normative data
  • General adult population average stress subscale scores: 4.73±4.20
  • Average stress subsection score above 12.27 correlate with clinical depression and generalized anxiety disorders
  • A change of 4.90 or more points in the anxiety subscore reliably represents clinical improvement.
8 Weeks
Evaluating the presence and severity of Kinesiophobia
Time Frame: 8 weeks

Assessed via the Shortened Tampa Scale for Kinesiophobia (TSK-11) electronically administered patient reported outcome questionnaire

  • The survey is a 11-question test scored from 11-44, where higher scores indicate increasing fear of movement.
  • A value of 11 is presumed in a nonpainful population.
  • Adults with chronic musculoskeletal pain undergoing outpatient chronic pain therapy report an average TSK score of 30.4 (+/- 6.6).
  • Successful evaluation of Kinesiophobia will be indicated if increases in TSK-11 scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents would also be considered a successful finding.
8 weeks
Evaluation of Resiliency
Time Frame: 8 weeks

Assessed via The Brief Resiliency Scale (BRS) electronically administered patient reported outcome questionnaire

  • An 8 question survey scored from 1-5 points
  • The average score for US adults age 24-34 is 3.2 (SD 0.7)
  • A statistically significant lower Grit score would be >1SD below this average value.
  • Successful evaluation of Grit will be indicated if increases in GRIT-S scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents would also be considered a successful finding.
8 weeks
Evaluation of Grit
Time Frame: 8 weeks

Assessed via The Short Grit Scale (GRIT-S) electronically administered patient reported outcome questionnaire

  • A 6-question test with low resiliency defined as a score of <3.00.
  • Prior descriptive studies indicate an average score of 3.57 (SD 0.76) for young adults age 19.8±3.0 years.
  • Statistically significant lower resilience would be >1SD below this average value.
  • Successful evaluation of Resiliency will be indicated if increases in GRIT-S scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents (for those tests where this data exists) would also be considered a successful finding.
8 weeks
Evaluating the presence and severity of Pain Catastrophizing
Time Frame: 8 weeks

Assessed via Pain Catastrophizing Scale (PCS) electronically administered patient reported outcome questionnaire

  • Scored on a 13 point scale.
  • Normative average values from a population of adults adults age 42.2 (17-63 years) with low back pain: mean 20.90 (SD 12.5),
  • Successful evaluation of Pain Catastrophization will be indicated if increases in PCS scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents would also be considered a successful finding.
8 weeks
Evaluating Self-Efficacy
Time Frame: 8 weeks

Assessed via The General Self-Efficacy Scale (GSE) electronically administered patient reported outcome questionnaire

  • 10-question test, scored from 10-40, with lower scores representing low self efficacy.
  • Average US adult values: 29.48 (SD 5.13)
  • Successful evaluation of Self-Efficacy will be indicated if increases in GSE scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents would also be considered a successful finding.
8 weeks
Evaluating the presence and severity of Alcohol Use Disorders
Time Frame: 8 weeks

Assessed via Alcohol Use Disorders Identification Test (AUDIT) electronically administered patient reported outcome questionnaire

  • A 10-question test with a threshold score >7 considered "AUDIT-positive", indicating risky or hazardous alcohol use behavior.
  • National data suggests 15-20% of US 14-18 year olds screen positive
  • Successful evaluation of Alcohol Use Disorders will be indicated if increases in AUDIT scores are found to be significantly associated with increased pain and decreased physical function (HOOS, PROMIS-PI, PROMIS-PB, PROMIS-PF) or increased self-reporting of opioid use.
  • The finding of no significant association, but increased presence of maladaptive features compared to normative data for US adolescents would also be considered a successful finding.
8 weeks
Changes in Physical Function (PROMIS)
Time Frame: 8 weeks

Measured via the following electronically administered patient reported outcome questionnaires.

  • PROMIS: Physical Function (PF)
  • Normative T-score generated from US adult population data: mean 50 (SD 10).
  • For this study, an average T-score <40 would be considered significantly different compared to normative values.
  • The minimally important difference (MID) of 1.9 - 2.2 calculated from research in nonoperative treatment of knee osteoarthritis will be representative of clinical improvement at eight weeks.
8 weeks
Changes in Physical Function (HOOS)
Time Frame: 8 weeks

Measured via the following electronically administered patient reported outcome questionnaires.

  • The Hip disability and osteoarthritis outcome score (HOOS)
  • Scored from 0-100
  • Increasing score represent better function.
  • Average scopres for hip preservation patients prior to surgery is well established
8 weeks
Reduced Opioid Use
Time Frame: 8 weeks
Measured via self reported opioid use after surgery
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Elizabeth Scott, MD, University of Iowa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2024

Primary Completion (Estimated)

August 1, 2025

Study Completion (Estimated)

August 1, 2025

Study Registration Dates

First Submitted

May 16, 2019

First Submitted That Met QC Criteria

July 28, 2019

First Posted (Actual)

July 31, 2019

Study Record Updates

Last Update Posted (Actual)

September 21, 2023

Last Update Submitted That Met QC Criteria

September 18, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Pain Chronic

Clinical Trials on Cell Phone Based Cognitive Based Therapy (Pacifica App)

3
Subscribe